Abstract 198P
Background
Women with breast cancer with impaired immunity develop life-threatening clinical disease. Findings of tumor-associated lymphocytes in tumor specimens are explicit evidence of immunologic sensitivity to this. Despite several treatment modalities, the majority of patients eventually relapse. However, immunotherapy – a new promising modality for treatment - has been advocated to command disease progress. Cancer immunoediting provided insights that the immune system has both immune surveillance and tumor promotion effects during cancer development. Anti-tumor immune response requires involvement of both CD4+ and CD8+ T cells. Thus, for better understanding the roles of CD4+ CD8 and regulatory T cells in pathogenesis and progression of breast cancer, the following study was designed to be conducted in clinical patients with breast cancer. 1-To determine expression of FOXP3 CD25, CD4, CD8 before therapy in blood, and tumor tissue. 2-Impact of surgery and chemotherapy on immunological status of tumour in breast cancer patients.
Methods
This was a prospective observational pilot study. Patients: N=30, locally advanced and metastatic breast cancer patients receiving chemotherapy as first modality of treatment (NACT group). N=30, early breast cancer patients receiving surgery as first modality of treatment (Upfront surgery). Control: N=30, Sex matched group undergoing surgery for benign breast disease.
Results
In the pre-treatment group lower expression of CD4 and higher CD8 and Tregs were found as the disease progresses. After upfront surgery CD4 counts increase with decrease of CD8 and Tregs cells. There was no change in CD4 in the control after surgery with positive correlation in CD8 and Tregs. Higher CD4 counts with lower CD8 and Tregs were found in patients after NACT.
Conclusions
T-cell subgroups in breast cancer patients undergo dynamic, significant changes during surgery and chemotherapy. Comprehensive analysis of characteristic T cell repertoire in breast cancer has depicted a landscape of possibilities of developing a blood-based therapeutic or preventive (vaccine) modality to enhance the armamentarium against this cancer.
Legal entity responsible for the study
AIIMS.
Funding
AIIMS New Delhi.
Disclosure
The author declared no conflicts of interest.
Resources from the same session
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
Resources:
Abstract
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
Resources:
Abstract
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
Resources:
Abstract
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
Resources:
Abstract
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
Resources:
Abstract
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
Resources:
Abstract
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
Resources:
Abstract
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
Resources:
Abstract
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract